Metagenomi Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Metagenomi, Inc. on June 10, 2025. The meeting was conducted virtually via live webcast. As of the record date (April 14, 2025), there were 37,382,478 shares of Common Stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals, both of which were approved:
- Proposal 1 (Director Election): Willard H. Dere, M.D. was elected as a Class I Director to serve until the 2028 annual meeting.
- For: 7,580,903
- Withheld: 2,891,893
- Broker Non-Votes: 8,292,425
- Proposal 2 (Auditor Ratification): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- For: 17,970,776
- Against: 252,634
- Abstentions: 541,811
A quorum was established with 18,765,221 shares present or represented by proxy.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Willard H. Dere, M.D. has been elected to the Board of Directors for a term ending in 2028.
- PricewaterhouseCoopers LLP has been ratified as the independent auditor for fiscal year 2025.
- Approximately 50.2% of outstanding shares were present or represented at the Annual Meeting.
- There were significant broker non-votes (8,292,425) regarding the director election, which did not affect the outcome but indicate shares held by brokers without voting instructions.